BioNTech Q2 2026 Earnings: Lower Vaccine Revenue Deepens Losses

BioNTech (Nasdaq: BNTX) reported Q2 2026 revenue of €105.6 million, down 59.5% from €260.8 million a year earlier, while IFRS diluted loss per share widened to €3.24 from €1.60. Lower COVID-19 vaccine demand, a higher cost base and pipeline-prioritization charges pushed the IFRS net loss to €820.8 million, although quarterly operating cash flow remained positive at €10.5 million and cash plus security investments totaled €16.6 billion.

Core Financial Results

The revenue decline was primarily caused by lower demand for BioNTech’s COVID-19 vaccines. Cost of sales nevertheless rose to €97.0 million from €76.4 million, sharply reducing the gross profit generated during the quarter.

Gross profit and gross margin are approximate calculations based on reported revenue and cost of sales. Adjusted figures are non-IFRS measures and should be considered alongside BioNTech’s IFRS results.

Commercial and Pipeline Performance

COVID-19 vaccines remained the main source of commercial revenue pressure. BioNTech cited softer global demand and said existing vaccine inventory in Germany would be used during the 2026 vaccination season. Separately, the European Commission approved the Pfizer-BioNTech XFG variant-adapted monovalent vaccine in July for the 2026–2027 season.

The oncology pipeline continued to move into later-stage development. BioNTech had 14 pivotal trials underway and initiated six during the first half, including five involving pumitamig and one evaluating the B7-H3-targeting antibody-drug conjugate elfetabart drozuntecan.

Pumitamig was being evaluated in seven pivotal trials. Phase 2 data in first-line non-small cell lung cancer showed encouraging activity across tumor histologies and PD-L1 expression levels, while the Phase 3 portion of the ROSETTA Lung-02 study was recruiting. BioNTech also expected a 2026 interim analysis from the Phase 3 gotistobart program and a fourth-quarter primary analysis from the Phase 3 DYNASTY-Breast02 trial of trastuzumab pamirtecan.

BioNTech also announced a leadership transition. Guido Oelkers was appointed to succeed co-founder Ugur Sahin as CEO and is expected to take office by February 1, 2027, at the latest.

Profitability, Cash Flow and Balance Sheet

R&D spending reflected higher investment in immuno-oncology and antibody-drug conjugate programs, particularly pumitamig and gotistobart, as well as intangible-asset impairments and the inclusion of CureVac operations acquired in late 2025. Lower spending on non-focus programs and collaboration cost-sharing partly offset these increases.

SG&A expense rose 44.0% due to pre-launch work, commercial expansion, CureVac operations and investment in process scaling and enterprise resource planning infrastructure. Cost reductions associated with pipeline prioritization and tighter spending discipline provided a partial offset.

Quarterly operating cash flow remained slightly positive despite the €820.8 million net loss. Major reconciling factors included €266.1 million of depreciation, amortization and impairment, a €366.0 million decrease in receivables, contract assets and other assets, and a €224.7 million working-capital contribution from changes in payables and other liabilities. For the first half, operating cash flow was negative €410.5 million, compared with negative €634.2 million a year earlier.

At June 30, BioNTech held €9.74 billion in cash and cash equivalents and €6.89 billion in current and non-current security investments, for combined liquidity investments of €16.63 billion. During Q2, the company repurchased 1.69 million ADSs at an average price of $89.50 under its authorization to buy back up to $1.0 billion through May 6, 2027.

Impairments and Prioritization Costs Enlarged the IFRS Loss

The difference between BioNTech’s IFRS and adjusted results was substantial in Q2. The company excluded €160.9 million of impairment-related items and €97.6 million of employee-related restructuring expenses from adjusted results, reducing the reported operating loss from €948.1 million to an adjusted €689.6 million.

The same adjustments reduced the net loss from €820.8 million under IFRS to €562.3 million on an adjusted basis. Within R&D, €73.9 million of intangible-asset impairment losses accounted for the difference between IFRS expense of €551.0 million and adjusted expense of €477.1 million. These figures show that both ongoing operations and portfolio-prioritization actions contributed to the wider quarterly loss.

2026 Guidance

BioNTech lowered its full-year revenue range because of softer COVID-19 vaccine demand, the use of existing German inventory and the deferral of milestone revenue from an out-licensed R&D program beyond 2026. It also reduced planned adjusted R&D spending as it prioritized its late-stage pipeline, while leaving SG&A guidance unchanged.

BioNTech continued to expect most 2026 revenue in the second half, particularly in Q3, when it expected to recognize €613 million of collaboration revenue from Bristol Myers Squibb.

Risks Investors Should Monitor

• Continued vaccine demand weakness: Softer global demand was the primary reason for both the quarterly revenue decline and the reduction in full-year guidance. Existing inventory in Germany adds another constraint for the 2026 vaccination season.
• Concentration and timing of revenue: Most full-year revenue is expected in the second half, including €613 million of anticipated BMS collaboration revenue in Q3. Changes in the timing of collaboration or milestone revenue could materially affect reported periods.
• High spending before oncology commercialization: BioNTech is funding multiple pivotal trials, pre-launch activities and commercial infrastructure while current product revenue is declining. First-half operating cash flow remained negative despite an improvement from the prior year.
• Clinical and regulatory execution: The company’s transition toward a multi-product oncology business depends on pivotal trial outcomes, regulatory submissions and approvals across several experimental programs.

Summary

BioNTech’s Q2 2026 results reflected a sharp decline in COVID-19 vaccine revenue alongside continued investment in oncology, commercial infrastructure and pipeline prioritization. Impairments and restructuring costs magnified the IFRS loss, while working-capital movements kept quarterly operating cash flow slightly positive and the company retained €16.6 billion in cash and security investments. The main near-term issues are execution against the reduced revenue guidance, recognition of expected second-half collaboration revenue and upcoming late-stage oncology readouts.